Literature DB >> 23188050

Can manipulation of splicing offer gene therapy possibilities to those with tumour-prone disorders?

D Gareth R Evans1, Andrew Wallace, William Newman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23188050      PMCID： PMC3722956          DOI： 10.1038/ejhg.2012.264

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN： 1018-4813            Impact factor:   4.246


× No keyword cloud information.
  7 in total

1.  Systemic administration of PRO051 in Duchenne's muscular dystrophy.

Authors:  Nathalie M Goemans; Mar Tulinius; Johanna T van den Akker; Brigitte E Burm; Peter F Ekhart; Niki Heuvelmans; Tjadine Holling; Anneke A Janson; Gerard J Platenburg; Jessica A Sipkens; J M Ad Sitsen; Annemieke Aartsma-Rus; Gert-Jan B van Ommen; Gunnar Buyse; Niklas Darin; Jan J Verschuuren; Giles V Campion; Sjef J de Kimpe; Judith C van Deutekom
Journal:  N Engl J Med       Date:  2011-03-23       Impact factor: 91.245

2.  Life expectancy in hereditary cancer predisposing diseases: an observational study.

Authors:  Anna Wilding; Sarah Louise Ingham; Fiona Lalloo; Tara Clancy; Susan M Huson; Anthony Moran; D Gareth Evans
Journal:  J Med Genet       Date:  2012-02-23       Impact factor: 6.318

Review 3.  Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.

Authors:  Tim W R Lee; Kevin W Southern
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

4.  Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.

Authors:  Karen Anthony; Lucy Feng; Virginia Arechavala-Gomeza; Michela Guglieri; Volker Straub; Katherine Bushby; Sebahattin Cirak; Jennifer Morgan; Francesco Muntoni
Journal:  Hum Gene Ther Methods       Date:  2012-10       Impact factor: 2.396

Review 5.  Gene therapy approaches for lysosomal storage disease: next-generation treatment.

Authors:  Barry J Byrne; Darin J Falk; Nathalie Clément; Cathryn S Mah
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

6.  In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2.

Authors:  Elisabeth Castellanos; Imma Rosas; Ares Solanes; Isabel Bielsa; Conxi Lázaro; Cristina Carrato; Cristina Hostalot; Pepe Prades; Francesc Roca-Ribas; Ignacio Blanco; Eduard Serra
Journal:  Eur J Hum Genet       Date:  2012-11-28       Impact factor: 4.246

7.  Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization.

Authors:  Leah A Owen; Hironori Uehara; Judd Cahoon; Wei Huang; Jacquelyn Simonis; Balamurali K Ambati
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.